Company news
Veracyte, Inc. (NASDAQ:VCYT) news
Every Veracyte, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
September 14, 2026
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 1, 2026
Veracyte Announces Second Quarter 2026 Financial Results
July 30, 2026
Veracyte : to Release Second Quarter 2026 Financial Results on July 30, 2026
July 9, 2026
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
July 9, 2026
Vaxcyte to Participate in Upcoming Investor Conferences
July 8, 2026
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
June 1, 2026
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
May 30, 2026
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
May 29, 2026
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
May 22, 2026
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
May 15, 2026
Veracyte Announces First Quarter 2026 Financial Results
May 5, 2026
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
April 28, 2026
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
April 14, 2026
Veracyte Names Kevin Haas as Chief Development and Technology Officer
March 16, 2026
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
February 25, 2026
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
February 24, 2026
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
February 4, 2026
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
January 11, 2026
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 29, 2025
Veracyte to Participate in Upcoming Investor Conferences
November 6, 2025
Veracyte Announces Third Quarter 2025 Financial Results
November 4, 2025
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
November 3, 2025
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
October 15, 2025
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
September 28, 2025
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
September 24, 2025
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
September 9, 2025
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
August 29, 2025
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
August 27, 2025
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
August 26, 2025
Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care
August 7, 2025
Veracyte Announces Second Quarter 2025 Financial Results
August 6, 2025
Veracyte Set to Join S&P SmallCap 600
July 24, 2025
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
July 17, 2025
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
July 8, 2025
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
May 28, 2025
Veracyte Announces First Quarter 2025 Financial Results
May 7, 2025
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
April 25, 2025
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
April 22, 2025
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
April 21, 2025
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
April 16, 2025
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
March 25, 2025
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
March 19, 2025
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
February 24, 2025
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
February 14, 2025
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
February 11, 2025
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
February 5, 2025
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
February 4, 2025
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
December 5, 2024
Veracyte Announces Third Quarter 2024 Financial Results
November 6, 2024